Metabolic Disorders in Multiple Myeloma

Multiple myeloma (MM) is the second most common hematological malignancy and is attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells including myeloma cells deregulate metabolic pathways to ensure proliferation, growth, survival and avoid immune surveillance, with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Gavriatopoulou, Stavroula A. Paschou, Ioannis Ntanasis-Stathopoulos, Meletios A. Dimopoulos
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	multiple myeloma metabolism glycolysis glutaminolysis metabolic syndrome Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/09e31b8548c4455aae403a9d8e95af86
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:09e31b8548c4455aae403a9d8e95af86
record_format	dspace
spelling	oai:doaj.org-article:09e31b8548c4455aae403a9d8e95af862021-11-11T16:53:56ZMetabolic Disorders in Multiple Myeloma10.3390/ijms2221114301422-00671661-6596https://doaj.org/article/09e31b8548c4455aae403a9d8e95af862021-10-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/21/11430https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Multiple myeloma (MM) is the second most common hematological malignancy and is attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells including myeloma cells deregulate metabolic pathways to ensure proliferation, growth, survival and avoid immune surveillance, with glycolysis and glutaminolysis being the most identified procedures involved. These disorders are considered a hallmark of cancer and the alterations performed ensure that enough energy is available for rapid cell proliferation. An association between metabolic syndrome, inflammatory cytokinesand incidence of MM has been also described, while the use of metformin and statins has been identified as a positive prognostic factor for the disease course. In this review, we aim to present the metabolic disorders that occur in multiple myeloma, the potential defects on the immune system and the potential advantage of targeting the dysregulated pathways in order to enhance antitumor therapeutics.Maria GavriatopoulouStavroula A. PaschouIoannis Ntanasis-StathopoulosMeletios A. DimopoulosMDPI AGarticlemultiple myelomametabolismglycolysisglutaminolysismetabolic syndromeBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 11430, p 11430 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple myeloma metabolism glycolysis glutaminolysis metabolic syndrome Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	multiple myeloma metabolism glycolysis glutaminolysis metabolic syndrome Biology (General) QH301-705.5 Chemistry QD1-999 Maria Gavriatopoulou Stavroula A. Paschou Ioannis Ntanasis-Stathopoulos Meletios A. Dimopoulos Metabolic Disorders in Multiple Myeloma
description	Multiple myeloma (MM) is the second most common hematological malignancy and is attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells including myeloma cells deregulate metabolic pathways to ensure proliferation, growth, survival and avoid immune surveillance, with glycolysis and glutaminolysis being the most identified procedures involved. These disorders are considered a hallmark of cancer and the alterations performed ensure that enough energy is available for rapid cell proliferation. An association between metabolic syndrome, inflammatory cytokinesand incidence of MM has been also described, while the use of metformin and statins has been identified as a positive prognostic factor for the disease course. In this review, we aim to present the metabolic disorders that occur in multiple myeloma, the potential defects on the immune system and the potential advantage of targeting the dysregulated pathways in order to enhance antitumor therapeutics.
format	article
author	Maria Gavriatopoulou Stavroula A. Paschou Ioannis Ntanasis-Stathopoulos Meletios A. Dimopoulos
author_facet	Maria Gavriatopoulou Stavroula A. Paschou Ioannis Ntanasis-Stathopoulos Meletios A. Dimopoulos
author_sort	Maria Gavriatopoulou
title	Metabolic Disorders in Multiple Myeloma
title_short	Metabolic Disorders in Multiple Myeloma
title_full	Metabolic Disorders in Multiple Myeloma
title_fullStr	Metabolic Disorders in Multiple Myeloma
title_full_unstemmed	Metabolic Disorders in Multiple Myeloma
title_sort	metabolic disorders in multiple myeloma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/09e31b8548c4455aae403a9d8e95af86
work_keys_str_mv	AT mariagavriatopoulou metabolicdisordersinmultiplemyeloma AT stavroulaapaschou metabolicdisordersinmultiplemyeloma AT ioannisntanasisstathopoulos metabolicdisordersinmultiplemyeloma AT meletiosadimopoulos metabolicdisordersinmultiplemyeloma
_version_	1718432160785891328

Metabolic Disorders in Multiple Myeloma

Ejemplares similares